her2-positive breast.

Breast Cancer Care in South India: Is Practice Concordant With National Guidelines?

Breast Cancer Care in South India: Is Practice Concordant With National Guidelines? J Glob Oncol. 2019 Jul;(5):1-7 Authors: Vijaykumar DK, Arun S, Abraham AG, Hopman W, Robinson AG, Booth CM Abstract PURPOSE: The National Cancer Grid (NCG) of India has recently published clinical practice guidelines that are relevant in the Indian context. We evaluated the extent to which breast cancer care at a teaching hospital in South India was concordant with NCG...

pubmed: her2-positive breast...

17m

Study: Patients with HER2-positive, stage IV breast cancer experienced better survival with surgery.

Study: Patients with HER2-positive, stage IV breast cancer experienced better survival with surgery. Cancer. 2019 Jul 15;125(14):2337 Authors: Printz C PMID: 31260096 [PubMed - in process]

pubmed: her2-positive breast...

17m

Relationship between 18-FDG-PET/CT and Clinicopathological Features and Pathological Responses in Patients with Locally Advanced Breast Cancers.

Relationship between 18-FDG-PET/CT and Clinicopathological Features and Pathological Responses in Patients with Locally Advanced Breast Cancers. Eurasian J Med. 2019 Jun;51(2):154-159 Authors: Yildirim N, Simsek M, Aldemir MN, Bilici M, Tekin SB Abstract Objective: We investigated the relationship between the maximum standardized uptake value (SUVmax) of whole-body positron emission tomography/computed tomography (PET/CT) performed before treatment and...

pubmed: her2-positive breast...

17m

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.

Related ArticlesTrastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019 Jun 27;: Authors: Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P Abstract BACKGROUND: Trastuzumab duocarmazine...

pubmed: her2-positive breast...

17m

Pathological complete response rates with pertuzumab-based neoadjuvant chemotherapy in breast cancer: A single-center experience.

Related ArticlesPathological complete response rates with pertuzumab-based neoadjuvant chemotherapy in breast cancer: A single-center experience. J Oncol Pharm Pract. 2019 Jun 29;:1078155219857800 Authors: Matthews CM, Nymberg K, Berger M, Vargo CA, Dempsey J, Li J, Ramaswamy B, Reinbolt R, Sardesai S, Wesolowski R, Williams N, Lustberg M Abstract BACKGROUND: Pertuzumab-based neoadjuvant chemotherapy (NAC) has demonstrated successful pathologic complete...

pubmed: her2-positive breast...

17m